About
En Carta Diagnostics is a Paris-based DeepTech startup focused on revolutionizing molecular diagnostics by making them accessible for at-home use. Their proprietary platform aims to deliver the precision of laboratory PCR tests with the ease of use of rapid tests, providing results in approximately 30 minutes. The company is initially targeting early detection of Lyme disease and expanding into STI screening.
Key facts
At-a-glance profile data
- Website
- encartadiagnostics.com
- Headquarters
- Paris, France
- Founded
- 2022
- Employees
- 12
- Total funding
- $5M (Seed)
- Business model
- B2B2C
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jul 2026 | Seed | $5M | - |
Frequently asked
What does En Carta Diagnostics do?
Their technology utilizes aptamers for high-affinity and specific target binding, allowing for a wide range of applications. En Carta Diagnostics is working towards regulatory certification in Europe and the US, industrializing production through a fabless model, and accelerating commercial launch.
How much funding has En Carta Diagnostics raised?
En Carta Diagnostics has raised a total of $5M in funding. The most recent round on record is Seed.
How many employees does En Carta Diagnostics have?
En Carta Diagnostics has approximately 12 people on record.
What is En Carta Diagnostics's current status?
En Carta Diagnostics's current operating status is: Inactive.